| Literature DB >> 27568838 |
Tao Fan1, Zhixin Huang2, Lei Chen1, Wei Wang1, Boyou Zhang1, Yao Xu1, Shize Pan1, Zhangfan Mao1, Hao Hu1, Qing Geng3.
Abstract
The activation of autophagy has been demonstrated to exert protective roles during hypoxia-reoxygenation (H/R)-induced brain injuries. This study aimed to investigate whether and how preconditioning with a proteasome inhibitor (MG-132), a proteasome promoter (Adriamycin, ADM), an autophagy inhibitor (3-methyladenine, 3-MA) and an autophagy promoter (Rapamycin, Rap) affected endoplasmic reticulum stress (ERS), the ubiquitin-proteasome system (UPS), autophagy, inflammation and apoptosis. Ubiquitin protein and 26S proteasome activity levels were decreased by MG-132 pretreatment but increased by ADM pretreatment at 2h, 4h and 6h following H/R treatment. MG-132 pretreatment led to the increased expression of autophagy-related genes, ER stress-associated genes and IκB but decreased the expression levels of NF-κB and caspase-3. ADM pretreatment led to the decreased expression of autophagy-related genes, ERS-associated genes and IκB but increased the expression of NF-κB and caspase-3. Pretreatment with 3-MA reduced the expression of autophagy-related genes, autophagy and UPS co-related genes, as well as apoptosis-related although the latter was increased by Rap pretreatment at 2h, 4h and 6h following H/R treatment. In vivo, pretreatment of rats with ADM, MG-132, 3-MA or Rap followed by ischemia-reperfusion (I/R) treatment resulted in similar changes. Proteasome inhibition preconditioning strengthened autophagy and ER stress but decreased apoptosis and inflammation. Autophagy promotion preconditioning exhibited similar changes. The combination of a proteasome inhibitor and an autophagy promoter might represent a new possible therapy to treat H/R or I/R injury-related diseases.Entities:
Keywords: 3-MA (PubChem CID: 1673); Adriamycin (PubChem CID: 31703); Alveolar macrophage; Autophagy; Endoplasmic reticulum stress; Hypoxia-reoxygenation injury; Ischemia-reperfusion injury; MG-132 (PubChem CID: 462382); Proteasome; Rapamycin (PubChem CID: 5284616)
Mesh:
Substances:
Year: 2016 PMID: 27568838 DOI: 10.1016/j.ejphar.2016.08.026
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432